<?xml version="1.0" encoding="UTF-8"?>
<p>The NPC cell line used here was manufactured by us in large quantities using our patented 13-passage cell culture system. We tested these cells pre-clinically for morphological and behavioral responses
 <sup>
  <xref rid="bibr35-0963689718820271" ref-type="bibr">35</xref>,
  <xref rid="bibr36-0963689718820271" ref-type="bibr">36</xref>
 </sup>. The source of these progenitor stem cells was first trimester human fetal tissue. These cells proliferate easily in culture
 <sup>
  <xref rid="bibr53-0963689718820271" ref-type="bibr">53</xref>,
  <xref rid="bibr54-0963689718820271" ref-type="bibr">54</xref>
 </sup> and are lessÂ likely to be rejected by transplant recipients due to expression of HLA-G
 <sup>
  <xref rid="bibr55-0963689718820271" ref-type="bibr">55</xref>
 </sup> and reduced immunogenicity
 <sup>
  <xref rid="bibr56-0963689718820271" ref-type="bibr">56</xref>
 </sup>. Furthermore, contrary to embryonic stem cells, the NPCs used here have been shown not to produce tumors in the standard teratoma assay
 <sup>
  <xref rid="bibr57-0963689718820271" ref-type="bibr">57</xref>
 </sup> (in-house data).
</p>
